Citius Pharmaceuticals Inc vs Western Digital Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Western Digital Corp trades at $456.56 (market cap $150.95B). The key difference: Western Digital Corp is far larger — about 7543.7× Citius Pharmaceuticals Inc's market cap, and Western Digital Corp pays a 0.14% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WDC | |
|---|---|---|
Market Cap | $20.01M | $150.95B |
Sector | Health | Technology |
52-Week High | $1.82 | $746.23 |
52-Week Low | $0.48 | $74.66 |
Enterprise Value | $16.23M | $150.42B |
Dividend Yield | — | 0.14% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Western Digital (WDC) trades at $438.12, up 0.88% on the day, with strong recent earnings performance beating expectations for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 72.95% net income margin and 131.02% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, though the stock faces valuation concerns after recent sell-offs.
The outlook remains positive with 72% analyst buy ratings and $665 consensus price target, representing 52% upside potential. Key risks include stretched valuation metrics (P/E 18.04, EV/EBITDA 30.24) and competitive threats from SSD adoption. The company's strong AI storage positioning and margin expansion provide growth opportunities, but investors should monitor execution against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →